1.66
0.01 (0.61%)
| Previous Close | 1.65 |
| Open | 1.64 |
| Volume | 42,122 |
| Avg. Volume (3M) | 64,767 |
| Market Cap | 42,164,784 |
| Price / Sales | 256.05 |
| Price / Book | 2.97 |
| 52 Weeks Range | |
| Earnings Date | 4 Aug 2025 - 8 Aug 2025 |
| Operating Margin (TTM) | -37,468.63% |
| Diluted EPS (TTM) | 3.38 |
| Quarterly Revenue Growth (YOY) | -51.70% |
| Quarterly Earnings Growth (YOY) | -19.50% |
| Total Debt/Equity (MRQ) | 26.43% |
| Current Ratio (MRQ) | 2.45 |
| Operating Cash Flow (TTM) | -19.88 M |
| Levered Free Cash Flow (TTM) | -11.33 M |
| Return on Assets (TTM) | -135.82% |
| Return on Equity (TTM) | -485.36% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Serina Therapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Relative Valuation | -5.0 |
| Financial Health | NA |
| AI Insight | NA |
| Weighted Average | -1.56 |
Select this tab to load the latest available analysis.
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 63.85% |
| % Held by Institutions | 3.37% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Waverly Advisors, Llc | 30 Jun 2026 | 67,492 |
| Keel Point, Llc | 30 Jun 2026 | 21,508 |
| Avidian Wealth Enterprises, Llc | 30 Sep 2026 | 18,800 |
No data within this time range.
No data within this time range.
AI Technical Analysis
Open the Technical tab to generate the latest analysis.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |